Premium
Chronic progressive myelopathy: its relation to the spinal progressive form of multiple sclerosis
Author(s) -
Steiner I.,
Feir G.,
Soffer D.,
Pleet A. B.,
Abramsky O.
Publication year - 1988
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1988.tb05886.x
Subject(s) - myelopathy , multiple sclerosis , medicine , amyotrophic lateral sclerosis , central nervous system disease , clinical significance , disease , spinal cord diseases , degenerative disease , pathology , spinal cord , immunology , psychiatry
— The causes and clinical features of chronic progressive myelopathy (CPM) were evaluated in a retrospective study of 107 patients. A special emphasis was put on those in whom no underlying cause for the myelopathy could be determined. Of 76 such, 39 (51%) had oligoclonal immunoglobulins (Ig) in the CSF and were therefore considered as possible MS, while the remainder, without oligoclonal Ig, were designated “myelopathy of unknown origin” (MUO). Our “possible MS” group was similar clinically to reported series of proven spinal MS, and it seems therefore, that the presence of oligoclonal Ig permits the recognition of a group of patiens with myelopathy who might be at a greater risk for MS. Patients with MUO differed from possible MS patients in several clinical characteristics, but most significantly in disease course and levels of functional disability which were more benign in the former. Myelopathy in possible MS patiens was also of a primary pyramidal and asymmetrical nature. It is therefore suggested that the segregation of patients with CPM of undetermined origin into 2 separate groups based on the presence or absence of oligoclonal Ig might be of prognostic significance.